Recent Trends in a Large HIV-1 Protease/Reverse Transcriptase and **Co-receptor Tropism Database** 

# Agnes C. Paquet\*, Mark C. Evans, Christos Petropoulos, Jeannette Whitcomb, Laura Napolitano, Mojgan Haddad

monooram

```
Monogram Biosciences,
South San Francisco
CAUSA
```

CXCR4-mediated entry is more prevalent among patient viruses with multiple drug class resistance (NRTI, NNRTI, and PI). DM (Dual-Mixed) refers to viral populations that utilize CCR5

Resistance mutations

L100

K103N

.....

Y181C.I.

G1904 S

Figure 5: Temporal trends of NNRTI-

K101E.P

. . . . . . .

V106A.M

and CXCR4 to enter CD4<sup>+</sup> cells

D67N

**IDR Spring Conference** 

Worcester, MA May 16, 2011

## BACKGROUND

• Drug resistance testing and co-receptor tropism determination are key components of the management of antiretroviral therapy for individuals infected with HIV-1.

• The purpose of this study was to examine phenotypic drug resistance patterns in protease-(PI), nucleoside-reverse-transcriptase- (NRTI), and non-nucleoside-reverse-transcriptaseinhibitors (NNRTI) over time, as well as prevalence of co-receptor usage by surveying Monogram's commercial patient testing database.

## METHODS

• We examined fully de-identified samples submitted for routine phenotypic and genotypic patient testing that show phenotypic resistance to at least one drug within PIs, NRTIs, and NNRTIs as measured by foldchange of IC50 (FC)  $\geq$  lower cutoff (CO).


• A total of 62,323 resistant samples collected from 2003 through 2009 were grouped into specimens that had FC  $\geq$  CO for minimum of 1 drug in each drug-class.

• We studied the temporal trends of % phenotypic 1-, 2-, and 3-class resistance and the prevalence of PI, NRTI and NNRTI resistance mutations (RAM)

• Furthermore, we examined the prevalence of CCR5 (R5) and CXCR4 (X4) using viruses among 6,949 samples that had genotypic PI, NRTI, and NNRTI resistance information as well as coreceptor tropism as determined by Monogram's Trofile assay.

• Jonckheere-Terpstra (JT) test was performed to evaluate the significance of trends.

## Figure 1: Trends of phenotypic 1-, 2- and 3-class resistance



Each bar represents the percentage of samples that exhibited reduced phenotypic susceptibility to either one, two, or three drug classes (NRTI, NNRTI, PI) compared to the sum total of all samples that exhibited reduced susceptibility to any drug class (i.e. NRTI, NNRTI, PI).

- 000 - 000 - 000

V82A.F.S.1

8 8 8 8 8 8 1

1 9014

## Figure 3: Temporal trends of PI-Resistance mutations

8 8 8 8 8 8 8


8 8 8 8 8 8

8 3 8 8 8 8 8 8

000 - 000 - 000 - 000

8 8 8 8 8 8 8

## Figure 4: Temporal trends of NRTI-Resistance mutations 147A.V



# Figure 2: Tropism distribution by genotypic class resistance | RESULTS



Monogram Biosciences, Inc. 345 Oyster Point Blvd. South San Francisco. CA 9408

single-class NRTI resistance (p=0.005).

• Prevalence of CXCR4 using viruses (DM + X4) among samples with matched PR/RT genotype was 35.7%, 41.4%, 47.1%, and 50.7% for 0-, 1-, 2-, and 3-class resistance, respectively

• The increase of X4 usage with increasing number of class resistance was statistically significant (p=0.02).

• The frequencies of major mutations associated with resistance to PI, NRTI and NNRTI are declining over time, except for RT positions 65 and 184 (NRTI RAM), RT positions 100, 103 and 225 (NNRTI), and PR positions 50, 54 and 88.

#### CONCLUSIONS

• A strong trend (2003-2009) of decreasing prevalence of 3-class resistance (NRTI, NNRTI, and PI) was identified in the Monogram Biosciences' commercial database.

 This was associated with an increased prevalence of single-class resistance.

 CXCR4-mediated entry was more prevalent among patient viruses with multiple drug class resistance.

• This trend may be due to the more advanced disease stage of treatment experienced natients

#### ACKNOWLEDGEMENTS

We are grateful to the Monogram Biosciences Clinical Reference Laboratory for performance of all phenotype and genotype assays.